Change is the only constant in healthtech. As founders and innovators, you’re navigating rapid scaling, shifting markets, and the accelerating impact of AI—all while needing to lead teams with confidence in uncertain times.

Join us for a HealthTech Hub Community Lunch with Natalka Designs, where we’ll explore practical tools and creative approaches to lead through growth, transformation, and complexity. This intimate session is designed to spark conversations, build resilience, and equip you with strategies to cut through the noise.

💡 What You’ll Learn

How to navigate the struggles of rapid scaling (team, culture, operations).
Strategies for leading confidently without “having all the answers.”
How to adapt to shifting markets and AI disruption.
Creative, neuroscience-led tools to transform uncertainty into opportunity.

👥 Speaker

Natalia Talkowska
Founder & CEO, Natalka Designs
For 15 years, Natalia has helped leaders and organisations worldwide cut through complexity to unlock clarity, growth, and transformation. Through a blend of advisory, creative direction, executive coaching, and storytelling, she has worked with global leaders including Salesforce, Google, Microsoft, META, Disney, the UK House of Commons, and Number 10 Downing Street.

Natalia is also a global keynote speaker, with appearances at SXSW (Austin, London, Sydney), Cannes Lions, MAD Fest, and the Scandinavian Creative AI Summit. Her mission is to help leaders harness creativity, resilience, and human connection in the age of AI.
"From chaos to clarity—we create the space for leaders to see what really matters."

Find out more about the Cicada HealthTech Hub

The Cicada HealthTech Hub is proudly supported by NSW Government and is part of the Westmead’s Health & Innovation District. The district includes 4 major hospitals, 4 world-leading medical research institutes, 2 university campuses and the largest research-intensive pathology service in NSW. By 2036, the number of full-time staff will increase to more than 50,000 and the number of students will expand to more than 10,000. Among the first projects for development is a viral vector advanced manufacturing facility to provide ground-breaking trial therapies for infections, cancer and genetic diseases.